PATENTSCOPE: EN_ALL:nmr AND PA:boehringer ingelheim

PYRIDINE CARBONYL DERIVATIVES AND THERAPEUTIC USES THEREOF AS TRPC6 INHIBITORS (Fri, 03 May 2019)
The invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R7, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
>> Read More

INTERMEDIATE COMPOUNDS AND METHDODS (Fri, 08 Feb 2019)
The present invention relates to compounds of (II) and an acceptable salt or hydrate thereof method of making same.
>> Read More

NOVEL N-[(PYRIMIDINYLAMINO)PROPANYL]-, N-[(PYRIDYLAMINO)PROPANYL] - AND N-[(PYRAZINYLAMINO)PROPANYL]ARYLCARBOXAMIDES (Fri, 08 Feb 2019)
The present invention relates to novel N-[(Pyrimidinylamino)propanyl]-, N-[(Pyridylamino)propanyl]- and N-[(Pyrazinylamino)propanyl]arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.
>> Read More

NOVEL SUBSTITUTED XANTHINE DERIVATIVES (Fri, 18 Jan 2019)
The present invention relates to substituted xanthine derivatives, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment of conditions having an association with TRPC5 containing ion channels.
>> Read More

HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS (Fri, 26 Oct 2018)
Heteroarylcarboxamides of formula (I), wherein A, T, R1, R2 and R3 are as defined in the specification and the claims, and pharmaceutically acceptable salts thereof can be used in methods for the treatment of diseases which can be influenced by inhibition of plasma kallikrein.
>> Read More

CYCLOPROPYL ALKYL AMINES AND PROCESS FOR THEIR PREPARATION (Fri, 12 Oct 2018)
The present invention relates to a process of making a compound of formula (I). Wherein, R is as defined herein.
>> Read More

MODIFIED CYCLIC DINUCLEOTIDE COMPOUNDS (Fri, 28 Sep 2018)
Compounds of formula (I) wherein Base1 and Base2 are defined as in claim 1 are modulators of STING.
>> Read More

TRANSITION METAL-CATALYZED PROTODECARBOXYLATION OF α-HALO-ACRYLIC ACID DERIVATIVES (Sat, 08 Sep 2018)
The present invention relates to a method for the synthesis of a halo olefin of formula (I) wherein Hal, R1, R2, R3, R4, X and Y are defined according to claim 1, or a salt thereof comprising the step of protodecarboxylation of an a-halo-acrylic acid derivative in the presence of a catalytic amount of copper and/or silver.
>> Read More

NEW MEDICAL USE OF COMPOUND III (Fri, 31 Aug 2018)
The present invention relates to compound III for the use in the treatment of diseases of the schizophrenia spectrum and other psychotic disorders, first episodes of these diseases like first episode of psychosis (FEP), relapses of these diseases like reduction of relapse in patients with schizophrenia (REX), polymorphs of compound III, and pharmaceutical compositions comprising compound III and/or its polymorphs.
>> Read More

INDANYLAMINOAZADIHYDROBENZOFURANYLACETIC ACIDS, PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DIABETES (Fri, 17 Aug 2018)
The present invention relates to compounds of general formula (I), wherein the groups R, R1, R2, m and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula (I).
>> Read More

BENZYLOXYPYRIDYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF (Fri, 03 Aug 2018)
The present invention relates to compounds of general formula (I), wherein the groups R, R1, R2, R3, m and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
>> Read More

INDANYLAMINOPYRAZINYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF (Fri, 03 Aug 2018)
The present invention relates to compounds of general formula (I) wherein the groups R, R1, R2, R3, m and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula (I).
>> Read More

BENZYLAMINOPYRIDYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICALCOMPOSITIONS AND USES THEREOF (Fri, 03 Aug 2018)
The present invention relates to compounds of general formula (I), wherein the groups R, R1, R2, R3, m and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
>> Read More

BENZYLOXYPYRAZINYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF (Fri, 03 Aug 2018)
The present invention relates to compounds of general formula (I), wherein the groups R, R1, R2, R3, m and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
>> Read More

BENZYLAMINOPYRAZINYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF (Fri, 03 Aug 2018)
The present invention relates to compounds of general formula (I), wherein the groups R, R1, R2, R3, m and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
>> Read More

NOVEL BENZYLAMINO SUBSTITUTED QUINAZOLINES AND DERIVATIVES AS SOS1 INHIBITORS (Fri, 29 Jun 2018)
The present invention encompasses compounds of formula (I), wherein the groups R1 to R7 have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
>> Read More

NEW 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS (Fri, 22 Jun 2018)
The present invention encompasses compounds of formula (I), wherein the groups R1 to R5, X, Y and W have the meanings given in the claims and specification, their use as inhibitors of BCL6, pharmaceutical compositions which contain compounds of this kind and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
>> Read More

NOVEL CHIRAL DIHYDROBENZOAZAPHOSPHOLE LIGANDS AND SYNTHESIS THEREOF (Fri, 15 Jun 2018)
This invention relates to novel phosphorous ligands useful for organic transformations. Methods of making and using the ligands in organic synthesis are described. The invention also relates to processes for preparing the novel ligands.
>> Read More

NOVEL CHIRAL DIHYDROBENZOOXAPHOSPHOLE LIGANDS AND SYNTHESIS THEREOF (Fri, 15 Jun 2018)
This invention relates to novel phosphorous ligands useful for organic transformations. Methods of making and using the ligands in organic synthesis are described. The invention also relates to processes for preparing the novel ligands
>> Read More

SULFONAMIDES AS INHIBITORS OF THE UPTAKE OF EXTRACELLULAR CITRATE (Fri, 15 Jun 2018)
Sulfonamides of formula (I), wherein A, R1, and R2 are as defined in the specification and the claims, can be used as medicaments for the treatment of metabolic and/or cardiovascular diseases.
>> Read More